ncRNA basic information
ncRNA ID:
MI0000103/MI0000739
ncRNA Database:
miRBase
ncRNA Name:
miR-101
ncRNA Type:
miRNA
ncRNA Expression:
up-regulated
ncRNA Method:
qRT-PCR
ncRNA Target Gene:
Jak2 and MCL-1
ncRNA Pathway:
NA
Evidence (ncRNA-drug):
validated
drug basic information
Drug ID:
DB00619 (APRD01028, EXPT02967, DB03261)
Drug Name:
Imatinib
Drug Method:
In the study, we transduced the K562 cell line with a miR-101-overexpressing vector and evaluated the Jak2 mRNA level. Our results showed that miR-101 overexpression in Bcr-Abl+ cells reduced the Jak2 mRNA level. Moreover, imatinib treatment and miR-101 upregulation led to miR-23a overexpression, which has putative binding site(s) on 3-untranslated regions (3-UTRs) of STAT5, CCND1, and Bcl-2 genes. Our results also indicated that miR-101 overexpression inhibited cell proliferation indicated by the MTT assay and promoted apoptosis detected via flow cytometry. Importantly, mRNA expression of NF-kappa B-regulated anti-apoptotic (Bcl-2, Bcl-xl, MCL-1, XIAP, and survivin) and proliferative (c-Myc and CCND1) genes was decreased. These findings suggest that miR-101 acts as a tumor suppressor by downregulating Jak2 expression and sensitizing K562 cells to imatinib.
Drug Response:
sensitive
Cancer basic information
Cancer:
chronic myeloid leukemia
Tissue/Cell:
cell line ( K562 )
Other information
Title:
miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-kappaB target genes.
Journal:
Tumour Biol
Published:
2016
PubMed ID:
27517565